Repligen (RGEN) Stock
Biologic medicine manufacturing materials and systems provider. Here's the price, business snapshot, and what's worth knowing about Repligen in October 2026.
Repligen Corporation is a specialised life‑sciences company that supplies consumables, materials and systems used in the manufacturing of biologic medicines such as monoclonal antibodies. Its product mix includes chromatography resins (notably Protein A), filtration systems and process‑intensification technologies that often generate recurring revenue from repeat purchases. The business benefits from long development cycles and close relationships with large biopharma customers, offering potentially resilient margins, but growth is tied to demand for biologics and capital spending in biomanufacturing. At a market capitalisation of about $8.8bn, Repligen can be seen as a mid/large‑cap service provider to the booming biologics industry. Key considerations for investors include product concentration, supply‑chain execution, competition and the potential for acquisitions to add scale. This is general educational information, not personal advice — values can fall as well as rise and suitability depends on your circumstances.
Repligen (RGEN) Stock Forecast
Analyst price target, next 12 months
$194.24
+6.9% vs today's $181.70
Price range over the last 12 months
Close to its 12-month high
Analysts covering Repligen have a consensus 12-month target of $194.24, above the current price of $181.70.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Repligen's stock with a target price of $194.24, indicating growth potential.
Financial Health
Repligen is performing well with strong sales, good profits, and solid cash flow generation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Recurring revenue model
Consumables such as resins and filters often lead to repeat sales, supporting stable revenue streams; however, past performance is not a guarantee of future results.
Process innovation focus
Solutions that increase manufacturing efficiency can drive adoption and higher margins, though technology cycles and competition may affect uptake.
Biologics market exposure
Demand for monoclonal antibodies and biosimilars supports long‑term growth potential, but revenue can be sensitive to industry spending and regulation.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
